| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Department of Veterans Affairs |
| Information provided by: | Department of Veterans Affairs |
| ClinicalTrials.gov Identifier: | NCT00018382 |
Purpose
This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.
| Condition | Intervention | Phase |
|
Alzheimer Disease |
Drug: rosiglitazone |
Phase II |
| Genetics Home Reference related topics: | Alzheimer disease |
| MedlinePlus related topics: | Alzheimer's Disease Memory |
| ChemIDplus related topics: | Insulin Rosiglitazone Rosiglitazone Maleate |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study |
| Official Title: | Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach |
Eligibility
| Ages Eligible for Study: | 55 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbid conditions.
Contacts and Locations| United States, Washington | |||||
| VA Puget Sound Health Care System | |||||
| Seattle, Washington, United States, 98108 | |||||
| Investigator: | Steven Kahn, M.D. | |
| Investigator: | Sanjay Asthana, M.D. | |
| Investigator: | Alfred Fujimoto, M.D. |
More Information
| Study ID Numbers: | AGCG-012-98S |
| First Received: | July 3, 2001 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00018382 |
| Health Authority: | United States: Federal Government |
|
|
|
|
